and patients with acute superÔ¨Åcial thrombophlebitis or
sepsis should not be treated with CAC.
The 5-year extension study of the VeClose (VenaSeal
Sapheon Closure System Pivotal Study) trial was recently
reported by Morrison et al.12 Freedom from recanalization at 5 years in the randomized CAC and RFA groups
was 91.4% and 85.2%, respectively,